CA2537060A1 - Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep - Google Patents
Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep Download PDFInfo
- Publication number
- CA2537060A1 CA2537060A1 CA002537060A CA2537060A CA2537060A1 CA 2537060 A1 CA2537060 A1 CA 2537060A1 CA 002537060 A CA002537060 A CA 002537060A CA 2537060 A CA2537060 A CA 2537060A CA 2537060 A1 CA2537060 A1 CA 2537060A1
- Authority
- CA
- Canada
- Prior art keywords
- day
- pain
- oxcarbazepine
- sleep
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 229960001816 oxcarbazepine Drugs 0.000 title claims abstract description 63
- 208000004296 neuralgia Diseases 0.000 title claims abstract description 45
- 208000021722 neuropathic pain Diseases 0.000 title claims abstract description 45
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 27
- 238000011282 treatment Methods 0.000 title claims abstract description 27
- 208000002193 Pain Diseases 0.000 claims abstract description 46
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 208000000094 Chronic Pain Diseases 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 27
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 239000007941 film coated tablet Substances 0.000 claims description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical class C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 239000003826 tablet Substances 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229940100692 oral suspension Drugs 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- -1 450 or 600 mg/day Chemical compound 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 229940061414 trileptal Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0320637A GB0320637D0 (en) | 2003-09-03 | 2003-09-03 | Organic compounds |
| GB0320637.2 | 2003-09-03 | ||
| US53737804P | 2004-01-16 | 2004-01-16 | |
| US60/537,378 | 2004-01-16 | ||
| PCT/EP2004/009797 WO2005020968A2 (en) | 2003-09-03 | 2004-09-02 | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2537060A1 true CA2537060A1 (en) | 2005-03-10 |
Family
ID=34276821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002537060A Abandoned CA2537060A1 (en) | 2003-09-03 | 2004-09-02 | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20060270658A1 (enExample) |
| EP (1) | EP1663247B1 (enExample) |
| JP (1) | JP2007513056A (enExample) |
| KR (1) | KR20060118426A (enExample) |
| AT (1) | ATE446759T1 (enExample) |
| AU (1) | AU2004268381B2 (enExample) |
| BR (1) | BRPI0414112A (enExample) |
| CA (1) | CA2537060A1 (enExample) |
| DE (1) | DE602004023861D1 (enExample) |
| IL (1) | IL173822A0 (enExample) |
| IS (1) | IS8373A (enExample) |
| MA (1) | MA28036A1 (enExample) |
| MX (1) | MXPA06002392A (enExample) |
| NO (1) | NO20061515L (enExample) |
| RU (1) | RU2369393C2 (enExample) |
| SG (1) | SG146631A1 (enExample) |
| TN (1) | TNSN06072A1 (enExample) |
| WO (1) | WO2005020968A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| GB0603008D0 (en) * | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
| MX2008013675A (es) * | 2006-04-26 | 2009-03-06 | Supernus Pharmaceuticals Inc | Preparaciones de liberacion controlada de oxcarbacepina que tienen perfil de liberacion sigmoidal. |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| KR102486435B1 (ko) | 2022-04-25 | 2023-01-10 | 주식회사 제이비플랜트 | 산업용 냉동기기의 친환경 패널의 제조 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH500196A (de) | 1969-03-10 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Azepinderivaten |
| US4353887A (en) | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
| CO4920215A1 (es) | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
| GB9925962D0 (en) * | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| GB9930058D0 (en) | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
| GB0128674D0 (en) * | 2001-11-30 | 2002-01-23 | Boots Co Plc | Treatment of sleep disorders and the like |
| CA2497780A1 (en) * | 2002-10-17 | 2004-04-29 | Novartis Ag | Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors |
-
2004
- 2004-09-02 WO PCT/EP2004/009797 patent/WO2005020968A2/en not_active Ceased
- 2004-09-02 JP JP2006525105A patent/JP2007513056A/ja active Pending
- 2004-09-02 CA CA002537060A patent/CA2537060A1/en not_active Abandoned
- 2004-09-02 US US10/570,340 patent/US20060270658A1/en not_active Abandoned
- 2004-09-02 AU AU2004268381A patent/AU2004268381B2/en not_active Ceased
- 2004-09-02 BR BRPI0414112-1A patent/BRPI0414112A/pt not_active IP Right Cessation
- 2004-09-02 DE DE602004023861T patent/DE602004023861D1/de not_active Expired - Lifetime
- 2004-09-02 RU RU2006110550/15A patent/RU2369393C2/ru not_active IP Right Cessation
- 2004-09-02 MX MXPA06002392A patent/MXPA06002392A/es not_active Application Discontinuation
- 2004-09-02 SG SG200806736-5A patent/SG146631A1/en unknown
- 2004-09-02 AT AT04764755T patent/ATE446759T1/de not_active IP Right Cessation
- 2004-09-02 EP EP04764755A patent/EP1663247B1/en not_active Expired - Lifetime
- 2004-09-02 KR KR1020067004340A patent/KR20060118426A/ko not_active Ceased
-
2006
- 2006-02-20 IL IL173822A patent/IL173822A0/en unknown
- 2006-03-02 TN TNP2006000072A patent/TNSN06072A1/en unknown
- 2006-03-10 MA MA28869A patent/MA28036A1/fr unknown
- 2006-03-24 IS IS8373A patent/IS8373A/is unknown
- 2006-04-03 NO NO20061515A patent/NO20061515L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SG146631A1 (en) | 2008-10-30 |
| US20060270658A1 (en) | 2006-11-30 |
| KR20060118426A (ko) | 2006-11-23 |
| WO2005020968A3 (en) | 2005-05-19 |
| BRPI0414112A (pt) | 2006-10-31 |
| MXPA06002392A (es) | 2006-06-20 |
| EP1663247B1 (en) | 2009-10-28 |
| IS8373A (is) | 2006-03-24 |
| JP2007513056A (ja) | 2007-05-24 |
| ATE446759T1 (de) | 2009-11-15 |
| AU2004268381B2 (en) | 2009-06-18 |
| TNSN06072A1 (en) | 2007-10-03 |
| DE602004023861D1 (de) | 2009-12-10 |
| WO2005020968A2 (en) | 2005-03-10 |
| RU2369393C2 (ru) | 2009-10-10 |
| MA28036A1 (fr) | 2006-07-03 |
| AU2004268381A1 (en) | 2005-03-10 |
| IL173822A0 (en) | 2006-07-05 |
| EP1663247A2 (en) | 2006-06-07 |
| RU2006110550A (ru) | 2007-12-20 |
| NO20061515L (no) | 2006-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ187097A3 (cs) | Farmaceutický prostředek | |
| KR20040007420A (ko) | 암로디핀 및 베나제프릴의 치료용 배합물 | |
| US11890261B2 (en) | Composition and method for treating neurological disease | |
| AU2009304002B9 (en) | A medicinal product and treatment | |
| US10500170B2 (en) | Composition and method for treating neurological disease | |
| AU2004268381B2 (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep | |
| US11833121B2 (en) | Composition and method for treating neurological disease | |
| US20180221380A1 (en) | Use of 5H-Dibenz/b,f/Azepine-5-Carboxamide Derivatives for Treating Fibromyalgia | |
| AU2003226753B2 (en) | Statin therapy for enhancing cognitive maintenance | |
| US20040058909A1 (en) | Method of treatment | |
| ZA200601502B (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and improvement of sleep | |
| US20230028539A1 (en) | Pharmaceutical composition, complementary kit and application thereof | |
| Baxter et al. | Twenty-four hour plasma profile of sustained-release isosorbide mononitrate in healthy volunteers and in patients with chronic stable angina. Two open label trials | |
| US20050124601A1 (en) | Methods for the treatment of bipolar disorder using carbamazepine | |
| US20060094709A1 (en) | Methods for the treatment of bipolar disorder using carbamazepine | |
| KR20220006049A (ko) | 신경병증성 통증의 치료를 위한 트라조돈을 포함하는 약학적 조합 | |
| US20080125414A1 (en) | Method of Treatment | |
| MXPA01006136A (en) | Combination of cerivastatin and fibrates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |